Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$48.91 -0.2%	$45.11	$21.72 ▼ $51.86	$9.35B	1.23	3.03 million shs	2.37 million shs
BPMC Blueprint Medicines	$129.46	$128.90	$73.04 ▼ $129.65	$8.36B	0.89	1.55 million shs	N/A
NAMS NewAmsterdam Pharma	$24.45 -3.7%	$21.41	$14.06 ▼ $27.29	$2.75B	-0.02	878,560 shs	711,628 shs
RVMD Revolution Medicines	$36.54 +0.2%	$37.84	$29.17 ▼ $62.40	$6.83B	1.16	1.87 million shs	2.00 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	-4.48%	+1.62%	+5.40%	+45.42%	+100.90%
BPMC Blueprint Medicines	0.00%	0.00%	0.00%	+25.69%	+38.47%
NAMS NewAmsterdam Pharma	+1.32%	+4.23%	+14.41%	+31.27%	+58.45%
RVMD Revolution Medicines	+0.36%	+5.04%	-4.83%	-9.93%	-14.94%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBIO BridgeBio Pharma	4.6865 of 5 stars	4.5	2.0	3.9	3.2	3.3	0.6
BPMC Blueprint Medicines	0.4553 of 5 stars	2.1	0.0	0.0	0.0	0.8	0.6
NAMS NewAmsterdam Pharma	3.5472 of 5 stars	4.4	1.0	0.0	2.7	5.0	0.0
RVMD Revolution Medicines	4.1686 of 5 stars	4.5	1.0	4.7	2.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	3.00	Buy	$61.35	25.44% Upside
BPMC Blueprint Medicines	2.11	Hold	$130.00	0.42% Upside
NAMS NewAmsterdam Pharma	2.89	Moderate Buy	$41.20	68.51% Upside
RVMD Revolution Medicines	3.00	Buy	$69.92	91.36% Upside

Current Analyst Ratings Breakdown

Latest NAMS, RVMD, BPMC, and BBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	RVMD Revolution Medicines	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$75.00
8/18/2025	RVMD Revolution Medicines	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$80.00
8/15/2025	RVMD Revolution Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$67.00
8/7/2025	NAMS NewAmsterdam Pharma	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$38.00 ➝ $39.00
8/7/2025	RVMD Revolution Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$57.00 ➝ $56.00
8/6/2025	BBIO BridgeBio Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$55.00 ➝ $57.00
8/6/2025	BBIO BridgeBio Pharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$60.00 ➝ $61.00
7/30/2025	BBIO BridgeBio Pharma	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$56.00
7/29/2025	BBIO BridgeBio Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$95.00
7/21/2025	BBIO BridgeBio Pharma	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$66.00
7/17/2025	NAMS NewAmsterdam Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$27.00

(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$221.90M	42.14	N/A	N/A	($7.71) per share	-6.34
BPMC Blueprint Medicines	$562.12M	14.87	N/A	N/A	$4.70 per share	27.54
NAMS NewAmsterdam Pharma	$45.56M	60.44	N/A	N/A	$8.20 per share	2.98
RVMD Revolution Medicines	$11.58M	589.85	N/A	N/A	$13.47 per share	2.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$535.76M	-$4.09	N/A	N/A	N/A	-329.25%	N/A	-85.69%	N/A
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	199.17	N/A	-27.70%	-64.60%	-17.22%	10/28/2025 (Estimated)
NAMS NewAmsterdam Pharma	-$241.60M	-$1.62	N/A	N/A	N/A	-259.07%	-27.27%	-25.00%	11/5/2025 (Estimated)
RVMD Revolution Medicines	-$600.09M	-$4.50	N/A	N/A	N/A	N/A	-41.78%	-35.63%	11/5/2025 (Estimated)

Latest NAMS, RVMD, BPMC, and BBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	NAMS NewAmsterdam Pharma	-$0.52	-$0.15	+$0.37	-$0.15	$1.44 million	$19.15 million
8/6/2025	Q2 2025	RVMD Revolution Medicines	-$0.94	-$1.31	-$0.37	-$1.31	$0.50 million	N/A
8/5/2025	Q2 2025	BBIO BridgeBio Pharma	-$0.83	-$0.95	-$0.12	-$0.95	$98.46 million	$110.57 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	5.19	5.08
BPMC Blueprint Medicines	1.01	2.80	2.75
NAMS NewAmsterdam Pharma	N/A	21.08	21.08
RVMD Revolution Medicines	0.13	11.79	11.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
BPMC Blueprint Medicines	N/A
NAMS NewAmsterdam Pharma	89.89%
RVMD Revolution Medicines	94.34%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	18.20%
BPMC Blueprint Medicines	4.21%
NAMS NewAmsterdam Pharma	20.84%
RVMD Revolution Medicines	8.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	400	191.17 million	156.38 million	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.86 million	Optionable
NAMS NewAmsterdam Pharma	4	112.63 million	89.16 million	Optionable
RVMD Revolution Medicines	250	186.93 million	171.60 million	Optionable

NAMS, RVMD, BPMC, and BBIO Headlines

Recent News About These Companies

LifeSci Capital Initiates Coverage of Revolution Medicines (RVMD) with Outperform Recommendation

August 19 at 8:13 AM | msn.com

Revolution Medicines initiated with an Overweight at Piper Sandler

August 18 at 9:24 PM | msn.com

Lord Abbett & CO. LLC Has $13 Million Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)

August 18 at 5:26 AM | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Coverage Initiated at Wells Fargo & Company

August 18 at 3:49 AM | americanbankingnews.com

Swiss National Bank Grows Position in Revolution Medicines, Inc. (NASDAQ:RVMD)

August 18 at 3:47 AM | marketbeat.com

Deutsche Bank AG Trims Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)

August 18 at 3:37 AM | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Receives $68.82 Consensus PT from Brokerages

August 18 at 2:41 AM | americanbankingnews.com

Revolution Medicines (NASDAQ:RVMD) Earns Overweight Rating from Analysts at Wells Fargo & Company

August 17 at 8:29 AM | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Given Consensus Recommendation of "Buy" by Brokerages

August 16 at 2:46 AM | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Shares Sold by E Fund Management Co. Ltd.

August 15, 2025 | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Shares Sold by Vanguard Group Inc.

August 15, 2025 | marketbeat.com

Aigen Investment Management LP Buys New Shares in Revolution Medicines, Inc. (NASDAQ:RVMD)

August 14, 2025 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Sells 28,639 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

August 14, 2025 | marketbeat.com

Analysts Are Bullish on These Healthcare Stocks: FibroGen (FGEN), Revolution Medicines (RVMD)

August 12, 2025 | theglobeandmail.com

Wedbush Equities Analysts Cut Earnings Estimates for RVMD

August 12, 2025 | americanbankingnews.com

Leerink Partnrs Has Pessimistic Outlook of RVMD Q3 Earnings

August 11, 2025 | marketbeat.com

Wedbush Research Analysts Cut Earnings Estimates for RVMD

August 11, 2025 | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Given New $56.00 Price Target at Needham & Company LLC

August 10, 2025 | americanbankingnews.com

Revolution Medicines (NASDAQ:RVMD) Shares Gap Down After Earnings Miss

August 8, 2025 | marketbeat.com

Needham & Company LLC Lowers Revolution Medicines (NASDAQ:RVMD) Price Target to $56.00

August 8, 2025 | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Shares Gap Down on Disappointing Earnings

August 8, 2025 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAMS, RVMD, BPMC, and BBIO Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$48.91 -0.11 (-0.22%)

Closing price 04:00 PM Eastern

Extended Trading

$48.88 -0.03 (-0.07%)

As of 07:09 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Blueprint Medicines NASDAQ:BPMC

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

NewAmsterdam Pharma NASDAQ:NAMS

$24.45 -0.95 (-3.74%)

Closing price 04:00 PM Eastern

Extended Trading

$24.42 -0.02 (-0.10%)

As of 06:51 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Revolution Medicines NASDAQ:RVMD

$36.54 +0.09 (+0.25%)

Closing price 04:00 PM Eastern

Extended Trading

$36.55 +0.01 (+0.03%)

As of 04:32 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time